Ftse Mib
37.236,20
-0,02%
DAX
21.962,20
0,13%
S&P 500
6.066,44
0,67%
NASDAQ
19.714,27
0,98%
Bitcoin
98.175,73
0,71%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Dyne Therapeutics Inc (DYN) Dyne Therapeutics Inc (DYN) Notizie

DYN

Dyne Therapeutics (DYN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DYN
DataOraFonteTitoloSimboloCompagnia
03/02/202513:30GlobeNewswire Inc.Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceNASDAQ:DYNDyne Therapeutics Inc
21/01/202513:30GlobeNewswire Inc.Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1NASDAQ:DYNDyne Therapeutics Inc
10/01/202512:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DYNDyne Therapeutics Inc
10/01/202512:30GlobeNewswire Inc.Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101NASDAQ:DYNDyne Therapeutics Inc
09/01/202513:30GlobeNewswire Inc.Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:DYNDyne Therapeutics Inc
08/01/202522:05GlobeNewswire Inc.Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ETNASDAQ:DYNDyne Therapeutics Inc
12/12/202402:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
11/12/202422:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
14/11/202415:27Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:DYNDyne Therapeutics Inc
12/11/202413:30GlobeNewswire Inc.Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:DYNDyne Therapeutics Inc
07/11/202422:15GlobeNewswire Inc.Dyne Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:DYNDyne Therapeutics Inc
09/10/202413:30GlobeNewswire Inc.Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular DiseasesNASDAQ:DYNDyne Therapeutics Inc
23/09/202414:56GlobeNewswire Inc.Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines ConferenceNASDAQ:DYNDyne Therapeutics Inc
04/09/202400:20Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
03/09/202412:31GlobeNewswire Inc.Dyne Therapeutics Announces Key Leadership AppointmentsNASDAQ:DYNDyne Therapeutics Inc
03/09/202412:30GlobeNewswire Inc.Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple CohortsNASDAQ:DYNDyne Therapeutics Inc
29/08/202413:30GlobeNewswire Inc.Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:DYNDyne Therapeutics Inc
14/08/202422:05Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:DYNDyne Therapeutics Inc
12/08/202423:10GlobeNewswire Inc.Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:DYNDyne Therapeutics Inc
12/08/202423:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DYNDyne Therapeutics Inc
24/06/202413:30GlobeNewswire Inc.Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe DiseaseNASDAQ:DYNDyne Therapeutics Inc
13/06/202422:40GlobeNewswire Inc.Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research CongressNASDAQ:DYNDyne Therapeutics Inc
30/05/202413:30GlobeNewswire Inc.Dyne Therapeutics to Present at Jefferies Global Healthcare ConferenceNASDAQ:DYNDyne Therapeutics Inc
28/05/202413:30GlobeNewswire Inc.Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesNASDAQ:DYNDyne Therapeutics Inc
22/05/202422:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DYNDyne Therapeutics Inc
22/05/202402:39GlobeNewswire Inc.Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
20/05/202422:01GlobeNewswire Inc.Dyne Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
20/05/202412:30GlobeNewswire Inc.Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional EndpointsNASDAQ:DYNDyne Therapeutics Inc
19/05/202414:00GlobeNewswire Inc.Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ETNASDAQ:DYNDyne Therapeutics Inc
02/05/202422:10GlobeNewswire Inc.Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:DYNDyne Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DYN

La tua Cronologia

BIT
UCG
Unicredit
BIT
TIT
Telecom Italia
BIT
BAMI
Banco BPM
BIT
MB
Mediobanca Banca di Cred...
BIT
ISP
Intesa Sanpaolo
BIT
ENI
Eni
BIT
BPE
Bper Banca
BIT
STLAM
Stellantis NV
BIT
IVG
Iveco Group NV
BIT
RACE
Ferrari NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENEL
Enel
BIT
BPSO
Banca Popolare di Sondrio
BIT
CPR
Davide Campari
BIT
STMMI
ST Microelectronics
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci